In the complex terrain of synthetic psychostimulants, few compounds have generated as much forensic scrutiny and clinical alarm as 3,4-methylenedioxypyrovalerone. Specifically within the Oceanic sphere, the regulatory and public health response to Methylenedioxypyrovalerone (MDPV) Australia has set critical precedents for how modern legislative bodies address novel psychoactive substances. Developed originally in the late 1960s as […]